AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools ...

Gad Soffer Joins as Chief Business Officer and Richard Silva, Ph.D., as Senior Vice President of Technical OperationsNEW YORK ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal ...

BRANFORD, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immunotherapy company developing first-in-category, multifunctional T Cell engager biotherapeutics to address unmet ...

In this piece, we will look at the stocks Jim Cramer recently discussed.

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund.

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares closed lower on Monday potentially following the company's announcement of Dan Kirby as Chief Commercial Officer.

Celgene has today confirmed that it will acquire Juno Therapeutics for $9 billion, and says the move will make it a leader in cell immunotherapy. The price is a significant premium on the $5.5 bn ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...